Screener
McKesson MCK Oncology & Multispecialty — Goodwill, transfer to held-for-sale
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | North American Pharmaceutical | Oncology & Multispecialty | Prescription Technology Solutions | Medical-Surgical Solutions | Total |
|---|---|---|---|---|---|
| Balance, March 31, 2026 | $2,781 | $3,963 | $2,065 | $2,507 | $11,316 |
| Goodwill acquired | — | 13 | — | — | 13 |
| Disposals | — | (2) | — | — | (2) |
| Foreign currency translation adjustments, net | (26) | — | — | — | (26) |
| Other adjustments (1) | — | (23) | — | — | (23) |
| Balance, June 30, 2026 | $2,755 | $3,951 | $2,065 | $2,507 | $11,278 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's oncology & multispecialty — goodwill, transfer to held-for-sale?
- McKesson (MCK) reported oncology & multispecialty — goodwill, transfer to held-for-sale of $2M in Q2 2026.
- How has McKesson's oncology & multispecialty — goodwill, transfer to held-for-sale changed year-over-year?
- McKesson's oncology & multispecialty — goodwill, transfer to held-for-sale decreased by 11.1% year-over-year, from $2.25M to $2M.
- What does oncology & multispecialty — goodwill, transfer to held-for-sale mean?
- The carrying value of goodwill associated with a business unit or asset group that has been classified as held for sale. This indicates a strategic divestiture or exit from a specific oncology or multispecialty market segment.
Ask your AI about McKesson's oncology & multispecialty — goodwill, transfer to held-for-sale.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude